InflaRx (NASDAQ:IFRX) is pausing activities related to a phase 3 trial of vilobelimab for treating hidradenitis suppurativa as the company seeks clarity on advice received from the FDA related to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback